March 23, 2021 -- Selexis and Tallac Therapeutics have signed both a commercial license agreement and service agreement to advance Tallac's toll-like receptor agonist antibody conjugate (TRAAC) platform.
Under the agreements, Tallac will use Selexis' proprietary Suretechnology platform to develop research cell banks to bring its immunotherapy candidates for the treatment of solid tumors to the clinic.
Tallac is developing therapeutics with the potential to activate innate and adaptive antitumor immunity. Its TRAAC platform, which delivers a potent toll-like receptor 9 agonist (T-CpG) for targeted immune activation via systemic administration, has been used to develop a pipeline of next-generation immunotherapies across multiple tumor indications.
Selexis' modular Suretechnology platform facilitates the rapid, stable, and cost-effective production of recombinant proteins and vaccines.